Sonnet BioTherapeutics Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SONN research report →
Companywww.sonnetbio.com
Sonnet BioTherapeutics Holdings, Inc. , a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
- CEO
- Raghu Rao
- IPO
- 2006
- Employees
- 13
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $8.43M
- P/E
- -0.32
- P/S
- 8.43
- P/B
- 0.48
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- -1584.41%
- Net Margin
- -1611.27%
- ROE
- -518.10%
- ROIC
- -144.22%
Growth & Income
- Revenue
- $1.00M · 5268.84%
- Net Income
- $-16,112,737 · -116.65%
- EPS
- $-3.95 · 65.20%
- Op Income
- $-15,844,115
- FCF YoY
- -49.02%
Performance & Tape
- 52W High
- $19.30
- 52W Low
- $1.08
- 50D MA
- $4.58
- 200D MA
- $3.04
- Beta
- 1.47
- Avg Volume
- 1.11M
Get TickerSpark's AI analysis on SONN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 25 | Kenney Richard T | other | 163,760 |
| Dec 2, 25 | Kenney Richard T | other | 86,505 |
| Dec 2, 25 | Kenney Richard T | other | 16,891 |
| Dec 2, 25 | Kenney Richard T | other | 86,505 |
| Dec 2, 25 | Kenney Richard T | other | 200 |
| Dec 2, 25 | Kenney Richard T | sell | 69,614 |
| Dec 2, 25 | Kenney Richard T | sell | 9,374 |
| Dec 2, 25 | Kenney Richard T | sell | 320,000 |
| Dec 2, 25 | Kenney Richard T | sell | 163,760 |
| Dec 2, 25 | MCANDREW STEPHEN J | sell | 6,446 |
Our SONN Coverage
We haven't published any research on SONN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SONN Report →